Skip to main content
European Commission logo print header

A precision, computer-vision measurement system for the early diagnosis of schizophrenia

Obiettivo

Strabismus, the disorder in which the eyes do not line up in the same direction, affects around 10.5 million Europeans.
Around 30% of strabismus surgeries need to be repeated due to inaccurate ocular measurements. At any point in time,
about 10% of the adult population will report having some type of mental or behavioral disorder, such as schizophrenia.
These two seemingly unrelated pathologies have one thing in common: they can be detected using ocular biomarkers. The
goal of this project is to validate ocular biomarkers for a range of pathologies, including ophthalmological, neurological,
mental, and endocrinological disorders. The clinical validations will be conducted using GazeLab, a computer vision-based
system that accurately measures ocular motility and pupillary dynamics. Our innovative all-in-one solution can be deployed
as a point-of-care diagnostic tool, leading to quicker and more effective treatments for a variety of disorders.
Strabismus patients are the first beneficiaries of our technology and are currently driving demand for GazeLab within the
ophthalmological sector. As we validate more biomarkers for ocular pathologies we will add value to our product for
ophthalmologists. Mental health professionals overwhelmingly diagnose subjectively, and can miss physiological symptoms
that ocular biomarkers can detect.
The goal of this SME Instrument phase 1 project is to determine if GazeLab represents a scalable, repeatable business model to help diagnose a variety of pathologies. If this is the case, we will proceed to request funding through phase 2. In phase 2 we aim to conduct large-scale validations necessary for GazeLab to be approved for the defined applications in a clinical setting. Our target markets include ophthalmologists, neuro-ophthalmologists, neurologists and psychiatrists. Our ultimate goal is to position GazeLab as the industry standard for precision ocular motility measurement and pupillography throughout a range of clinical specialties

Invito a presentare proposte

H2020-SMEInst-2014-2015

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEINST-1-2015

Meccanismo di finanziamento

SME-1 - SME instrument phase 1
æ

Coordinatore

BCNINNOVA TECHNOLOGICAL EVOLUTION SL
Contribution nette de l'UE
€ 50 000,00
Indirizzo
Calle covadonga 378 4 1 a
08203 Barcelona
Spagna

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
Este Cataluña Barcelona
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Altri finanziamenti
€ 21 429,00